<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9871">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711555</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0363</org_study_id>
    <nct_id>NCT00711555</nct_id>
    <nct_alias>NCT00229489</nct_alias>
  </id_info>
  <brief_title>Emend for Multiple-day Emetogenic Chemotherapy</brief_title>
  <official_title>An Open Label Phase II Study of Aprepitant for Multi-day Moderately-high to Highly Emetogenic Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effect of Emend (aprepitant) on nausea and
      vomiting associated with chemotherapy. Chemotherapy commonly causes nausea and vomiting and
      this affects patients' quality of life and attitudes toward treatment. Although nausea and
      vomiting associated with chemotherapy has been decreasing due to improved therapy, some
      patients will still experience this side effect. Therefore, new medications are needed to
      decrease the amount of nausea and vomiting patients have with chemotherapy. Emend
      (aprepitant) is a new medication used to treat nausea and vomiting with chemotherapy, but it
      has only been studied in patients receiving only one dose of chemotherapy that makes most
      people sick. However, there is little experience with this medication in patients receiving
      multiple days of chemotherapy that causes nausea and vomiting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the studies leading to aprepitant's approval, subjects received only one dose of highly
      emetogenic chemotherapy. Campos et al studied subjects who received their first course of
      cisplatin containing chemotherapy that included a cisplatin dose 70mg/m2 and reported that
      aprepitant in addition to granisetron and dexamethasone increased the number of subjects
      without acute or delayed emesis (p&lt;0.01). A similar study done by Poli-Bigelli et al
      indicated that adding aprepitant to a standard antiemetic regimen increased the percentage
      of subjects without emesis and using rescue therapy during the acute phase (83% to 69%; p &lt;
      0.001). Adding aprepitant also increased the percentage of subjects with no emesis or use of
      rescue medications in the delayed phase (68% vs. 47%, p&lt;0.001). Although these studies
      demonstrate the benefits of aprepitant for a one day chemotherapy regimen, the benefits of
      adding aprepitant to current standard antiemetic therapy (dexamethasone plus a serotonin
      receptor antagonist) in subjects receiving multiple days of moderately-high to highly
      emetogenic chemotherapy have not been examined within a clinical study. We hypothesize that
      aprepitant with dexamethasone and a serotonin receptor antagonist from days one to two days
      after finishing chemotherapy will decrease nausea for subjects receiving chemotherapy
      regimens that include multiple days of treatment with moderately-high to highly emetogenic
      chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>cycle 1, day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Protection</measure>
    <time_frame>cycle 1, day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>no Emesis</measure>
    <time_frame>cycle 1, day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>no Nausea</measure>
    <time_frame>cycle 1, day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>no Significant Nausea</measure>
    <time_frame>cycle 1, day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant, ondansetron, dexamethasone</intervention_name>
    <description>On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.
FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.
FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a life expectancy &gt; 3 months

          -  Subjects with an ECOG performance score &lt; 3

          -  Subjects with access to a telephone for follow-up

          -  Subjects able to swallow tablets and capsules

        Exclusion Criteria:

          -  Subjects who previously received aprepitant as prophylaxis for chemotherapy induced
             nausea and vomiting.

          -  Subjects with an allergy, hypersensitivity, or contraindication to aprepitant,
             dexamethasone, prochlorperazine or a serotonin receptor antagonist.

          -  Subject with uncontrolled diabetes or a concurrent illness/condition requiring
             chronic systemic steroids or pre-existing gastrointestinal pathology.

          -  Subjects with a history of excessive alcohol consumption.

          -  Women who are pregnant or lactating.

          -  Subjects with nausea at baseline or chronically using other antiemetic agent(s).

          -  Subjects currently receiving another investigational agent.

          -  Subjects taking a medication that can interact with aprepitant, including the
             following medications:

               -  warfarin

               -  oral contraceptives

               -  tolbutamide

               -  phenytoin

               -  midazolam

               -  ketoconazole

               -  rifampin

               -  paroxetine

               -  diltiazem

          -  Subjects with poor hepatic or renal function defined as AST &gt; 3 x ULN, ALT &gt; 3 x ULN,
             total bilirubin &gt; 3 x ULN, alkaline phosphatase &gt; 3 x ULN or serum creatinine &gt;2
             mg/dl measured within three months before starting chemotherapy.

        Subjects with hepatic metastases with AST &gt; 5 x ULN, ALT &gt; 5 x ULN, total bilirubin &gt; 5 x
        ULN, alkaline phosphatase &gt; 5 x ULN.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Illinois Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 6, 2009</lastchanged_date>
  <firstreceived_date>July 3, 2008</firstreceived_date>
  <firstreceived_results_date>June 11, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Stacy S. Shord, Assistant Professor</name_title>
    <organization>University of Illinois at Chicago</organization>
  </responsible_party>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>multiple days</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>serotonin receptor antagonist</keyword>
  <keyword>quality of life</keyword>
  <keyword>therapy</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>aprepitant</keyword>
  <keyword>rescue therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Emetics</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42" spread="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response</title>
        <description>defined as a no emetic episodes and no use of rescue therapy</description>
        <time_frame>cycle 1, day 1</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Complete Response</title>
            <description>defined as a no emetic episodes and no use of rescue therapy</description>
            <units>%</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Protection</title>
        <description>defined as no emesis, no use of rescue medications, and a maximum nausea severity &lt; 25 mm (100 mm visual analog scale, 0 = no nausea, 100 = worst nausea)</description>
        <time_frame>cycle 1, day 1</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Complete Protection</title>
            <description>defined as no emesis, no use of rescue medications, and a maximum nausea severity &lt; 25 mm (100 mm visual analog scale, 0 = no nausea, 100 = worst nausea)</description>
            <units>%</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>no Emesis</title>
        <time_frame>cycle 1, day 1</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>no Emesis</title>
            <units>%</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>no Nausea</title>
        <description>defined as maximum nausea severity &lt; 5 mm (100 mm visual analog scale, 0 = no nausea, 100 = worst nausea)</description>
        <time_frame>cycle 1, day 1</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>no Nausea</title>
            <description>defined as maximum nausea severity &lt; 5 mm (100 mm visual analog scale, 0 = no nausea, 100 = worst nausea)</description>
            <units>%</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>no Significant Nausea</title>
        <description>defined as a maximum nausea severity &lt; 25 mm (100 mm visual analog scale, 0 = no nausea, 100 = worst nausea)</description>
        <time_frame>cycle 1, day 1</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant, Dexamethasone, Ondansetron, Multiple Days</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>no Significant Nausea</title>
            <description>defined as a maximum nausea severity &lt; 25 mm (100 mm visual analog scale, 0 = no nausea, 100 = worst nausea)</description>
            <units>%</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandra Cuellar</name_or_title>
      <organization>University of Illinois</organization>
      <phone>312-996-6985</phone>
      <email>scuell1@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
